Design of experiments

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors

Friday, March 5, 2021 - 4:00pm

Athenex investors have until May 3, 2021 to file a lead plaintiff motion.

Key Points: 
  • Athenex investors have until May 3, 2021 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • As a result, the FDA had recommended that Athenex conduct additional clinical trials and employ certain risk mitigation strategies to improve toxicity.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®

Friday, March 5, 2021 - 1:44pm

The continued peer-reviewed publications of our Nyxol clinical trial results allow us to highlight the iris dilator mechanism and emerging product profile of Nyxol.

Key Points: 
  • The continued peer-reviewed publications of our Nyxol clinical trial results allow us to highlight the iris dilator mechanism and emerging product profile of Nyxol.
  • The recently enrolled MIRA-2 Phase 3 pivotal trial leveraged the design and findings of the MIRA-1 Phase 2b trial, said Mina Sooch, MBA, President and CEO of Ocuphire Pharma.
  • Treatment with Nyxol eye drops led to a reduction in time to return to baseline pupil diameter of nearly 2 hours when compared to placebo.
  • The MIRA-1 results informed the trial design of the Phase 3 MIRA-2 registration trial that recently completed recruitment.

Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA

Friday, March 5, 2021 - 1:00pm

Kintor has been the first China-based biopharma company whose small-molecule novel drug was granted with a phase III clinical trial approval by the FDA for the treatment of COVID-19.

Key Points: 
  • Kintor has been the first China-based biopharma company whose small-molecule novel drug was granted with a phase III clinical trial approval by the FDA for the treatment of COVID-19.
  • Dr. Tong Youzhi, the Founder, Chairman and CEO of Kintor Pharmaceutical, commented, "We are delighted to receive this phase III clinical trial approval from the FDA.
  • This has been the first phase III clinical trial approval from the FDA since Kintor's inception in 2009.
  • We are driving at full force to execute clinical operations of this phase III clinical trial.

Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board

Tuesday, March 2, 2021 - 2:00pm

Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board.

Key Points: 
  • Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board.
  • Craig is a recognized visionary leader who has spent his career dedicated to transforming some of the most challenging issues in clinical research through new innovations.
  • The core mission of DTRA is making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
  • We are honored to have Craig as the chair of our Industry Advisory Board.

VirTrial Launches eConsent Solution as Stand-Alone Offering or Bundled With Its Telemedicine Platform

Tuesday, March 2, 2021 - 2:00pm

SCOTTSDALE, Ariz., March 2, 2021 /PRNewswire/ -- VirTrial today announcedthe general availability ofSmartSignalseConsent,a PDF-based,clinical trialconsentsolutionofferingrapid implementationand aflexible, scalable, and lightweightdesign.

Key Points: 
  • SCOTTSDALE, Ariz., March 2, 2021 /PRNewswire/ -- VirTrial today announcedthe general availability ofSmartSignalseConsent,a PDF-based,clinical trialconsentsolutionofferingrapid implementationand aflexible, scalable, and lightweightdesign.
  • The producthelps trial teams quicklyset up e-consenting functionalityand enablesstudy sites to greatly reducetheeffort to route and manage documents for signature.
  • It does soby leveraging existing PDF documents approvedby IRBs and ethics committeesthat are then seamlessly converted to accept digital signatures.
  • IncorporatingVirTrial'svirtual visits into study protocols opens the doortoa wider participant pool, ultimately yielding improved study outcomes and efficient site performance.

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization

Tuesday, March 2, 2021 - 1:30pm

Our methods to produce psilocybin and other tryptamines are expected to result in cheaper, faster and cleaner products than any other published methods.

Key Points: 
  • Our methods to produce psilocybin and other tryptamines are expected to result in cheaper, faster and cleaner products than any other published methods.
  • Pharmaceutical grade psilocybin is currently being produced for clinical trials and research activities using a chemical synthesis process.
  • (1) PsyBio has developed a biosynthetic process using readily available materials, which undergoes a two to four day, one pot autocatalytic process.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials.

Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences

Tuesday, March 2, 2021 - 11:00am

H.C. Wainwright Global Life Sciences Conference 2021:

Key Points: 
  • H.C. Wainwright Global Life Sciences Conference 2021:
    The Company will be participating in the H.C. Wainwright Global Life Sciences Conference with a virtual presentation that will be available on demand beginning on March 9th.
  • The BIO-Europe Spring 2021 program content includes business development, therapeutic areas, startup innovations, digital health, and scheduled one-on-one meetings.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow us on Twitter at https://twitter.com/GreenwichLS .

Global Glioma Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Tuesday, March 2, 2021 - 9:59am

The "Global Glioma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Glioma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Glioma Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Glioma market.
  • It covers emerging therapies for Glioma in active clinical development stages including early and late stage clinical trials.
  • The report provides Glioma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Best Practices to Scale Global Hybrid Decentralized Studies, Upcoming Webinar Hosted by Xtalks

Monday, March 1, 2021 - 1:30pm

TORONTO, March 1, 2021 /PRNewswire-PRWeb/ -- More sponsors are seeking to launch and execute decentralized clinical trials (DCTs) than ever before.

Key Points: 
  • TORONTO, March 1, 2021 /PRNewswire-PRWeb/ -- More sponsors are seeking to launch and execute decentralized clinical trials (DCTs) than ever before.
  • In 2020, COVID-19 catalyzed the already growing rate of DCT studies as many active studies without decentralized approaches were transitioned to support patient safety and trial continuity.
  • For more information, or to register for this event, visit Best Practices to Scale Global Hybrid Decentralized Studies.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Medable Partners With Seqster to Integrate Real-World Patient Data Streams in Decentralized Clinical Trials

Monday, March 1, 2021 - 12:37pm

Medable Inc. , the leading cloud platform for patient-centered drug development, today announced a new partnership with Seqster to integrate real-time, real-world data streams into decentralized clinical trials.

Key Points: 
  • Medable Inc. , the leading cloud platform for patient-centered drug development, today announced a new partnership with Seqster to integrate real-time, real-world data streams into decentralized clinical trials.
  • Medable will integrate Seqster technology into its decentralized trial platform to streamline trial recruitment and participation, resulting in efficiency and cost savings while maintaining patient data ownership, privacy, and security.
  • Patients want clinical trials to fit into their real-world experience, not the other way around, said Dr. Michelle Longmire , CEO and co-founder of Medable.
  • Working with Seqster, we can integrate more data sources and data streams to provide clinicians with a more holistic view of patient health, leading to higher-quality trial results while simplifying the patient experience.